A VEGF receptor vaccine demonstrates preliminary efficacy in Neurofibromatosis type 2. Contributor Nature Comms Behind the paper A VEGF receptor vaccine demonstrates preliminary efficacy in Neurofibromatosis type 2. Masahiro Toda Dec 17, 2019
